Previous 10 | Next 10 |
Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial Anapt...
ANAB has a wholly-owned pipeline and partnered pipeline. ANAB has an upcoming catalyst in Q1'21, results from the POPLAR trial of ANB019 in palmoplantar pustulosis. Insights from a trial of a similar drug from Boehringer Ingelheim in palmoplantar pustulosis suggest ANAB is not gua...
AnaptysBio (NASDAQ: ANAB) closed more than 10% higher on Friday. This followed news that a drug the company partnered on has received a positive opinion from an important multinational health agency. On Friday, the European Union's (EU) European Medicines Agency's Committee for ...
AnaptysBio (ANAB): Q4 GAAP EPS of $1.20 beats by $0.15.Revenue of $60M (+1900.0% Y/Y) beats by $5M.Press Release For further details see: AnaptysBio EPS beats by $0.15, beats on revenue
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe generalized pustular psoriasis (GPP) announced in October 2020, with Phase 3 trial initiation anticipated in mid-2021 Topline data from POPLAR Phase 2 imsidolimab clinical trial in palmop...
On Tuesday, AnaptysBio (NASDAQ: ANAB) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play. AnaptysBio is a clinical-stage biotech that concentrate...
AnaptysBio (NASDAQ: ANAB) rose by just over 11% on Thursday, as a high-profile bank has become more optimistic on the stock, to put it lightly. J.P. Morgan analyst Anupam Rama upgraded his recommendation on AnaptysBio stock. In his estimation, it's now overweight (i.e., buy), fr...
AnaptysBio has a number of molecules in pipeline and in partnered programs, but it has a history of failures for one molecule. The company's cash position is good. Because of that one molecule's poor history, I will avoid ANAB for now. For further details see: AnaptysBio...
J.P. Morgan has upgraded AnaptysBio (ANAB) to overweight from underperform noting a ‘positive reward/risk profile’ in the company’s Phase 2 trial for interleukin-36 receptor antagonist imsidolimab in Palmoplantar pustulosis (“PPP”).The price target is raised...
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announce...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...